Aarti Pharmalabs (AARTIPHARM) | Stock Overview & Key Data
Aarti Pharmalabs Performance Comparison
Stock Range
Today's Range
Low: ₹820.05
High: ₹834.95
on October 3, 2025
52 Week Range
Low: ₹557.05
High: ₹971.00
on December 19, 2024
All-Time High: ₹971.00 on July 16, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR75.0B
EPS
29.43
P/E Ratio (TTM)
28.27
Forward P/E
N/A
P/B Ratio
3.79
PEG Ratio
-2.62
Div. Yield
0.40%
ROE
13.69%
Beta
-0.536
Debt to Equity
20.76
Financial Highlights
Profitability
Gross Margin
56.13%
Operating Margin
18.76%
Profit Margin
13.69%
Returns and Earnings
Return on Assets (TTM)
9.37%
Return on Equity (TTM)
13.69%
EBITDA
INR4.7B
Net Income (TTM)
INR2.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR214.68
Quarterly Revenue Growth (YoY)
-30.50%
Quarterly Earnings Growth (YoY)
-10.70%
Dividend Information
Last 12-Month Dividend
₹3.50
Current Dividend Yield
0.40%
3-Year Average Dividend Yield
0.24%
3-Year Average Annual Dividend
₹2.11
3-Year Total Dividends
₹6.34
Ex-Dividend Date
February 14, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Aarti Pharmalabs AARTIPHARM | 75.00B Mid-cap | 0.35% | -5.95% | -8.57% | 2.47% | 18.24% | 33.12% | 218.65% | 218.65% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Neuland Laboratories NEULANDLAB | 198.78B Mid-cap | 8.80% | 5.76% | 30.23% | 26.07% | 6.30% | 25.94% | 926.28% | 1,106.52% |
| Alembic APLLTD | 182.09B Mid-cap | 0.05% | -4.74% | -9.63% | 2.62% | -13.21% | -26.75% | 47.43% | -5.00% |
| Jubilant Pharmova JUBLPHARMA | 171.19B Mid-cap | -0.50% | 3.66% | -10.84% | 17.71% | -0.05% | -2.93% | 210.44% | 101.03% |
Ownership & Short Interest
Insider Ownership
44.37%
Institutional Ownership
11.09%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
529K
Average 90-Day Volume
345K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AARTIPHARM's 52-week high and low?
- In the last 52 weeks, Aarti Pharmalabs reached a high of ₹971.00 (on N/A) and a low of ₹557.05 (on December 19, 2024).
- What is the market cap and P/E ratio for AARTIPHARM?
- Curious about Aarti Pharmalabs's size and valuation? Its market capitalization stands at 75.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is 28.27, and the forward P/E (looking ahead) is N/A.
- Does AARTIPHARM pay dividends? If so, what's the yield?
- Yes, Aarti Pharmalabs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.40%, and the company has paid an average of ₹2.11 per share annually over the past 3 years.
- Who are Aarti Pharmalabs's main competitors or similar companies to consider before investing?
When looking at Aarti Pharmalabs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Neuland Laboratories
NEULANDLAB198.78B Healthcare Drug Manufacturers - Specialty & Generic 25.94% 926.28% Alembic
APLLTD182.09B Healthcare Drug Manufacturers - Specialty & Generic -26.75% 47.43% Jubilant Pharmova
JUBLPHARMA171.19B Healthcare Drug Manufacturers - Specialty & Generic -2.93% 210.44% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aarti Pharmalabs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Aarti Pharmalabs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.69%, the Debt to Equity ratio from the most recent quarter is 20.76, and its Gross Profit Margin stands at 56.13%.
- What is the recent revenue and earnings growth for AARTIPHARM?
- Looking at Aarti Pharmalabs's growth, its revenue over the trailing twelve months (TTM) was INR19B. Compared to the same quarter last year (YoY), quarterly revenue grew by -30.50%, and quarterly earnings saw a YoY growth of -10.70%.
- How much of AARTIPHARM stock is held by insiders and institutions?
- Wondering who owns Aarti Pharmalabs stock? Company insiders (like executives and directors) hold about 44.37% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 11.09%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.